Drugs / Lutrepulse
Lutrepulse
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07152730 | Sep → Oct 2025 | amenorrhea, infertility disorder | Ferring Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00296465 | Feb → Nov 2005 | female infertility | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01457703 | Jun 2010 → Jul 2013 | obesity disorder | University of Colorado, Denver | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lutrepulse | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07152730 ↗ |
| Known as | Gonadorelin-GnRH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01457703 ↗ |
| Known as | Pulsatile gonadotropin-releasing hormone (GnRH) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00296465 ↗ |
| Action | Activate | “GnRH is used to stimulate the pituitary gland to produce LH and FSH.” NCT01457703 ↗ |
| Route | Intravenous | “administered either subcutaneously (SC) or intraveneously (IV) as specified” NCT00296465 ↗ |
| Route | Subcutaneous | “administered either subcutaneously (SC) or intraveneously (IV) as specified” NCT00296465 ↗ |